| Not Yet Recruiting | MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors NCT05676489 | University of Alabama at Birmingham | EARLY_Phase 1 |
| Recruiting | A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma NCT07074756 | Mayo Clinic | N/A |
| Recruiting | PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial NCT06397560 | Baptist Health South Florida | N/A |
| Recruiting | Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatmen NCT05859334 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Niraparib In Recurrent IDH 1/2 Gliomas NCT05406700 | Massachusetts General Hospital | EARLY_Phase 1 |
| Recruiting | CARv3-TEAM-E T Cells in Glioblastoma NCT05660369 | Marcela V. Maus, M.D.,Ph.D. | Phase 1 |
| Unknown | Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence NCT05611645 | Huashan Hospital | Phase 2 |
| Terminated | PARP Inhibition for Gliomas (PI-4G or π4g) NCT05297864 | University of Oklahoma | Phase 2 |
| Active Not Recruiting | Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma NCT05045027 | Jonsson Comprehensive Cancer Center | EARLY_Phase 1 |
| Unknown | Personalized Vaccine for Patients With Recurrent Malignant Glioma NCT04943718 | Xuanwu Hospital, Beijing | Phase 1 |
| Recruiting | A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tu NCT04794972 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd NCT04740190 | The University of Hong Kong | Phase 2 |
| Unknown | Role of Surgery in Treatment of Recurrent Brian Glioma:Prognostic Factors and Outcome NCT04562077 | Assiut University | — |
| Active Not Recruiting | Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 M NCT04164901 | Institut de Recherches Internationales Servier | Phase 3 |
| Completed | A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas NCT04089449 | Prelude Therapeutics | Phase 1 |
| Terminated | Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases NCT03796273 | Wake Forest University Health Sciences | EARLY_Phase 1 |
| Active Not Recruiting | Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Muta NCT03212274 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders Wi NCT03698994 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma NCT03389230 | City of Hope Medical Center | Phase 1 |
| Completed | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Ly NCT03526250 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Accelerated Hypofractionated Intensity - Modulated Radiotherapy After Hyperbaric Oxygenation for Recurrent Hig NCT03411408 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | N/A |
| Unknown | Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas NCT04216550 | The First Affiliated Hospital of Zhengzhou University | — |
| Completed | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03213678 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213665 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hist NCT03233204 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213704 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc NCT03155620 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymph NCT02465060 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma NCT01580969 | University of Utah | Phase 1 / Phase 2 |
| Terminated | Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors NCT01324635 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 |